4 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow Kineta Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants LHF-535 - Healthy | Phase 1 | Completed | Kineta Inc. | 24 | 2019-09-16 | 2020-07-09 |
| A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis dalazatide, placebo - Plaque Psoriasis | Phase 1 | Completed | Kineta Inc. | 24 | 2014-10-01 | 2015-05-06 |
| Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers dalazatide, placebo - Healthy | Phase 1 | Completed | Kineta Inc. | 32 | 2013-11-01 | 2015-05-18 |
Breast Neoplasms (1) · Carcinoma (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemorrhagic Fevers, Viral (1) · Kidney Neoplasms (1) · Lassa Fever (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Psoriasis (1)
Shk-186 peptide (2) · pembrolizumab (1)
United States (2) · Australia (1) · Canada (1)
Shawn Iadonato, PhD (2) · Thierry Guillaudeux, PhD (1)